MADDEN SECURITIES Corp Purchases New Position in GSK plc (NYSE:GSK)

MADDEN SECURITIES Corp acquired a new position in GSK plc (NYSE:GSK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 87,430 shares of the pharmaceutical company’s stock, valued at approximately $2,957,000. GSK makes up about 1.2% of MADDEN SECURITIES Corp’s investment portfolio, making the stock its 22nd largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its position in shares of GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after acquiring an additional 323 shares during the period. Rehmann Capital Advisory Group boosted its stake in shares of GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares in the last quarter. Investment Partners Asset Management Inc. grew its position in shares of GSK by 2.3% during the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock valued at $636,000 after acquiring an additional 344 shares during the period. Finally, Bond & Devick Financial Network Inc. increased its stake in shares of GSK by 5.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock valued at $320,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

Shares of NYSE:GSK opened at $36.45 on Tuesday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.53. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The firm has a market capitalization of $75.53 billion, a PE ratio of 22.92, a P/E/G ratio of 1.42 and a beta of 0.64. The business’s 50 day moving average price is $34.25 and its 200-day moving average price is $37.55.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities research analysts expect that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.31%. GSK’s dividend payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.